Benzalkonium chloride antagonises aminoglycoside antibiotics and promotes evolution of resistance

Biocide disinfectants are essential tools in infection control, but their use can inadvertently contribute to emergence of antibiotic-resistant bacteria. In this study we systematically examine the effect of the biocide benzalkonium chloride, which is primarily used for surface disinfection but is a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EBioMedicine 2021-11, Vol.73, p.103653-103653, Article 103653
Hauptverfasser: Short, Francesca L, Lee, Victor, Mamun, Rafa, Malmberg, Robert, Li, Liping, Espinosa, Monica I, Abbu, Kristel-Ione, Algie, Jarrod, Callaghan, Amy, Cenderawasih-Nere, Priscilla, Cullen, Victoria, Gooden, Meredith, Kanoun, Mayes, Lawrie, Angus, Maher, Justin, Malek, Vanessa, Safdari, Zahra, Shehadie, Benjamin, Shifa, Shaila-Yasmin, Simpson, Irene, Towns, Madeleine, Valter, Stefan, Venkatesan, Koushik, Paulsen, Ian T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Biocide disinfectants are essential tools in infection control, but their use can inadvertently contribute to emergence of antibiotic-resistant bacteria. In this study we systematically examine the effect of the biocide benzalkonium chloride, which is primarily used for surface disinfection but is also present as a preservative in many consumer products, on the activity of aminoglycoside antibiotics in Acinetobacter baumannii. The effect of subinhibitory BAC on aminoglycoside treatment of A. baumannii ATCC17978 was investigated using time-to-kill assays, MIC determination, directed evolution experiments, fluctuation tests and labelled gentamicin accumulation assays. Further MIC determinations and directed evolution experiments were performed with additional Gram-negative ESKAPE pathogens. In A. baumannii ATCC17978, BAC prevents gentamicin killing and drastically increases the frequency at which resistant mutants emerge, through reducing intracellular antibiotic accumulation. BAC also increases the MIC of multiple aminoglycoside antibiotics (kanamycin, tobramycin, streptomycin, gentamicin and amikacin). BAC promotes the emergence of mutants with reduced gentamicin susceptibility in other Gram-negative ESKAPE pathogens but does not always alter the MIC. These effects occur at BAC concentrations which are similar to residual levels in high-use environments, and just below the concentration range for BAC when used as a preservative in eye drops and ear drops. Our results suggest that subinhibitory BAC has the potential to antagonise aminoglycoside activity and promote the emergence of bacterial mutants with reduced susceptibility. We suggest that the extremely widespread use of BAC in clinical and home settings and its long half-life mean there is potential for these interactions to occur in the environment, or in patients who use BAC-containing products while taking aminoglycosides to treat skin, eye or ear infections, although such co-exposure is likely to be rare. We suggest that biocide stewardship is needed to prevent the types of exposure that can contribute to antibiotic resistance. This work was funded by the National Health and Medical Research Council of Australia. The funders had no role in study design, interpretation or decision to publish.
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2021.103653